VAP-1抑制剂及其应用领域的专利分析  

Patent statistics and analysis about using of vascular adhesion protein-1 inhibitor

作　　者：焦士勇[1] 段洁[1] 王鑫[1] 杨倩[1] 黄旸木[2] 

机构地区：[1]国家知识产权局专利局专利审查协作北京中心,北京100190 [2]北京大学医学部,北京100191

出　　处：《中国当代医药》2015年第20期12-15,共4页China Modern Medicine

基　　金：中国博士后科学基金(2014M560027)

摘　　要：血管黏附蛋白(VAP)与众多疾病的发生相关,是众多疾病治疗的靶点。本文通过运用CNABS,DWPI,Sipoabs数据库进行检索和分析,统计涉及VAP-1的专利申请,从专利的年申请量、申请人、技术领域、涉及的疾病治疗领域进行分析,供相关药物研发企业参考,统计结果显示目前涉及VAP-1的全球专利申请数量偏少,申请主要来源于欧美日等西方国家,涉及VAP-1的药物研发公司还没有完成相关专利的布局,这在一定程度上为我国申请人在相关领域的研发提供了机遇。Vascular adhesion protein-1 （VAP-1） is related to the occurrence of numerous diseases and is target of many diseases.The information on annual application amount,applicant,technology and treatment field was analyzed by combinational utilization of CNABS,DWPI and Sipoabs databases,to provide research and development suggestions for related pharmaceutical companies.The restdts show that the number of global patent applications related to VAP-I is quite small.The applications mainly come from western countries such as Europe,America and Japan.Companies in- volved in VAP-1 has not completed the layout of the relevant patents,which might provide an opportunity ＇for Chinese applicants of in this relevant field.

关 键 词：血管黏附蛋白 专利 统计分析 技术领域 

分 类 号：R977.6[医药卫生—药品]